cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
17 July – Members of Unison at 14 Scottish council areas, including Glasgow, Perth and Kinross and Dumfries and Galloway, vote to take industrial action after describing a pay offer from COSLA as "inadequate". 19 July – Unison rejects the latest offer from Cosla aimed at preventing strikes by refuse collectors, which was worth 3.2%. 21 July – Data from Public Health Scotland for the week ending 14 July indicates there were 1,130 cases of COVID-19 in Scotland, but the health body believes cases may have peaked. 22 July – Following the death of 17-year-old Jonathan Beadle at Polmont Young Offenders Institution on Saturday 13 July, the Scottish Government announces that nobody under the age of 18 will be kept in prison in Scotland from the week beginning 2 September. Unite and the GMB follow Unison in rejecting the latest pay offer for refuse workers from Cosla. 23 July – The family of Allan Marshall, who died after being restrained by 17 prison officers at HMP Edinburgh in 2015, are to sue the Scottish Government under human rights legislation in what is believed to be the first case of its kind. 24 July – Researchers from the Scottish Association for Marine Science report evidence of dark oxygen being produced from manganese nodules on the seafloor. It was previously assumed that almost all the free oxygen (O2) on Earth was created through photosynthesis, which requires sunlight. The research has since come under criticism for methodological and ethical issues.
Beyond storing and releasing elastic energy, fascial tissues contribute to proprioception and motor control through dense innervation with mechanoreceptors and nociceptors. Recent biomechanical studies also emphasize the role of fascial networks in distributing strain across multiple joints. This is an idea often framed as a body-wide tensegrity system, so that fascia participates dynamically in coordinated movement and postural stability.
=== DNA chips === Early biochips were based on the idea of a DNA microarray, e.g., the GeneChip DNAarray from Affymetrix, which is a piece of glass, plastic or silicon substrate, on which pieces of DNA (probes) are affixed in a microscopic array. Similar to a DNA microarray, a protein array is a miniature array where a multitude of different capture agents, most frequently monoclonal antibodies, are deposited on a chip surface; they are used to determine the presence and/or amount of proteins in biological samples, e.g., blood. A drawback of DNA and protein arrays is that they are neither reconfigurable nor scalable after manufacture. Digital microfluidics has been described as a means for carrying out Digital PCR.
Sources: en.wikipedia.org
=== SIRVD model === The susceptible-infected-recovered-vaccinated-deceased (SIRVD) epidemic compartment model extends the SIR model to include the effects of vaccination campaigns and time-dependent fatality rates on epidemic outbreaks. It encompasses the SIR, SIRV, SIRD, and SI models as special cases, with individual time-dependent rates governing transitions between different fractions. This model uses the following system of differential equations for the population fractions
Lori stated that he would be taking a sabbatical from the program until he recovers. She blamed the stroke on Bakker's hard work on his show and wrote that he had described the criticism against him as "the most vicious attack that he has ever experienced". Bakker returned to his program for the first time following his stroke on July 8, 2020. On June 23, 2021, Missouri Attorney General Eric Schmitt announced the settlement of the state's lawsuit against Bakker. Bakker and Morningside Church would be prohibited from saying silver solution could "diagnose, prevent, mitigate, treat, or cure any disease or illness". Restitution of about $157,000 would also be paid to those who bought silver solution between February 12, 2020, and March 10, 2020.
These controls are utilized to sort the droplets in response to some signal detection from the droplets such as fluorescence intensity. Precise sorting methods utilize these active sorting methods by first making a decision (e.g., fluorescence signal) about the droplets then altering their flow with one of the aforementioned methods. A technique called Fluorescent Activated Droplet Sorting (FADS) has been developed which utilizes electric field-induced active sorting with fluorescent detection to sort up to 2000 droplets per second. The method relies on, but is not limited to, enzymatic activity of compartmentalized target cells to activate a fluorogenic substrate within the droplet. When a fluorescing droplet is detected, two electrodes are switched on applying a field to the droplet, which shifts its course into the selection channel, while non-fluorescing droplets flow through the main channel to waste. Other methods utilize different selection criteria, such as absorbance or transmittance of droplet, number of encapsulated particles, or image recognition of cell shapes. Sorting can be done to improve encapsulation purity, an important factor for collecting sample for further experiments.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.